TWI894224B - 用於肌肉萎縮性脊髓側索硬化症之治療的低劑量人類介白素-2 - Google Patents

用於肌肉萎縮性脊髓側索硬化症之治療的低劑量人類介白素-2

Info

Publication number
TWI894224B
TWI894224B TW110107972A TW110107972A TWI894224B TW I894224 B TWI894224 B TW I894224B TW 110107972 A TW110107972 A TW 110107972A TW 110107972 A TW110107972 A TW 110107972A TW I894224 B TWI894224 B TW I894224B
Authority
TW
Taiwan
Prior art keywords
human
treatment
administered
tregs
als
Prior art date
Application number
TW110107972A
Other languages
English (en)
Chinese (zh)
Other versions
TW202146041A (zh
Inventor
吉爾伯特 班西蒙
彼得 Ｎ 萊格
提摩太 翠伊
塞西莉亞 加蘭達
馬西莫 洛卡蒂
珍妮 奇爾比
帕梅拉 紹
安德里亞 馬拉帕辛
Original Assignee
尼姆大學醫學中心
義大利商仁愛米拉索萊股份有限公司
薩塞克斯大學
倫敦國王學院
瑪麗女王倫敦大學
索邦大學
巴黎公立醫院聯盟
雪菲爾大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 尼姆大學醫學中心, 義大利商仁愛米拉索萊股份有限公司, 薩塞克斯大學, 倫敦國王學院, 瑪麗女王倫敦大學, 索邦大學, 巴黎公立醫院聯盟, 雪菲爾大學 filed Critical 尼姆大學醫學中心
Publication of TW202146041A publication Critical patent/TW202146041A/zh
Application granted granted Critical
Publication of TWI894224B publication Critical patent/TWI894224B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW110107972A 2020-03-06 2021-03-05 用於肌肉萎縮性脊髓側索硬化症之治療的低劑量人類介白素-2 TWI894224B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305241.0 2020-03-06
EP20305241 2020-03-06

Publications (2)

Publication Number Publication Date
TW202146041A TW202146041A (zh) 2021-12-16
TWI894224B true TWI894224B (zh) 2025-08-21

Family

ID=71083549

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110107972A TWI894224B (zh) 2020-03-06 2021-03-05 用於肌肉萎縮性脊髓側索硬化症之治療的低劑量人類介白素-2

Country Status (8)

Country Link
US (2) US20230090069A1 (https=)
EP (2) EP4647123A3 (https=)
JP (1) JP7840267B2 (https=)
AU (1) AU2021230103A1 (https=)
CA (1) CA3166887A1 (https=)
ES (1) ES3041723T3 (https=)
TW (1) TWI894224B (https=)
WO (1) WO2021176044A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4630035A1 (en) 2022-12-05 2025-10-15 Centre Hospitalier Universitaire de Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
AU2024238511A1 (en) * 2023-03-21 2025-10-02 Coya Therapeutics, Inc. Biomarkers of amyotrophic lateral sclerosis and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4656132A (en) 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
RU2322452C2 (ru) * 2006-03-27 2008-04-20 Михаил Николаевич Смирнов Иммуномодулирующая композиция
DK2683395T3 (en) 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
JP7422480B2 (ja) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Camu, William et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine vol. 59 Elsevier Epub 2020 Jul 7 102844

Also Published As

Publication number Publication date
AU2021230103A1 (en) 2022-09-22
EP4114440C0 (en) 2025-06-25
US20230090069A1 (en) 2023-03-23
JP7840267B2 (ja) 2026-04-03
CA3166887A1 (en) 2021-09-10
EP4114440B1 (en) 2025-06-25
TW202146041A (zh) 2021-12-16
EP4647123A3 (en) 2025-12-24
JP2023516774A (ja) 2023-04-20
US20240335510A1 (en) 2024-10-10
EP4647123A2 (en) 2025-11-12
ES3041723T3 (en) 2025-11-14
WO2021176044A1 (en) 2021-09-10
EP4114440A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
Zhang et al. Neuroinflammation in Alzheimer’s disease: insights from peripheral immune cells
Rosenzwajg et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study
Macrez et al. Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities
Lattanzi et al. Unraveling the enigma of new‐onset refractory status epilepticus: a systematic review of aetiologies
Herting et al. Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema
Biswas et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice
DK2683395T3 (en) USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
Takeuchi et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)
US20240335510A1 (en) Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
Huang et al. Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor–1 for lung fibrosis
US9937154B2 (en) Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
Shibata et al. Myelin basic protein autoantibodies, white matter disease and stroke outcome
Etzioni Leukocyte adhesion deficiency syndromes
CA2490186A1 (en) Method for the treatment of multiple sclerosis
Sezer et al. Serum cytokine levels and periodontal parameters in ankylosing spondylitis
Imazu et al. Ustekinumab decreases circulating Th17 cells in ulcerative colitis
Yetkin Ay et al. The impact of the IL‐11: IL‐17 ratio on the chronic periodontitis pathogenesis: a preliminary report
Svanberg Teglgaard et al. Improved innate immune function in patients with chronic lymphocytic leukemia treated with targeted therapy in clinical trials
Morawiec et al. The comparative analysis of selected interleukins and proinflammatory factors in CSF among de novo diagnosed patients with RRMS
Cifuentes-González et al. Biological and therapeutic role of Interleukin-6 in non-infectious uveitis: a narrative review
Anno et al. Change of autoantibody levels in established rheumatoid arthritis patients treated by biological disease-modifying anti-rheumatic drugs-the AIRTIGHT study
KR101970007B1 (ko) 자가면역 질환의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법
Li et al. Neuroimmune crosstalk in Parkinson’s disease: the pivotal role of microglia and infiltrating T cells
CN111658643B (zh) 雷帕霉素在难治性Graves病中的制药应用
Kobayashi et al. Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry